<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477592</url>
  </required_header>
  <id_info>
    <org_study_id>仁济伦审[2014]116K</org_study_id>
    <nct_id>NCT02477592</nct_id>
  </id_info>
  <brief_title>a Novel Individualized Substrate Modification Approach for the Treatment of Long-standing Persistent Atrial Fibrillation</brief_title>
  <official_title>A Prospective Randomized Study of a Novel Individualized Substrate Modification Approach Versus Stepwise Ablation for the Treatment of Long-standing Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effectiveness of two substrate modification
      approaches in long-standing persistent atrial fibrillation patients, and hypothesized that a
      substrate-based, individualized substrate modification (ISM)approach should be superior to
      traditional stepwise ablation(SA). To the best of investigator's knowledge, this was the
      first study to evaluate the &quot;real&quot; substrate by means of electro-anatomic mapping and to
      perform &quot;true&quot; substrate modification in long standing persistent atrial fibrillation
      ablation(LPAF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter ablation (CA) is highly effective for paroxysmal atrial fibrillation(AF), it is
      modestly effective for long standing persistent atrial fibrillation ablation(LPAF) even with
      complex or combined approaches, which is mainly attributed to the substrate underlying AF
      remodeling. Severity of atrial fibrosis is closely associated with clinical outcomes after CA
      for AF . The more atrial scars and fibrosis present, the lower the success rate for AF
      ablation. Patients with LPAF have many more areas with scars and fibrosis than those with
      paroxysmal AF or non-AF controls. The MRI delayed enhancement technique provides a
      non-interventional tool for evaluation of atrial fibrosis, however, it must be performed in
      sinus rhythm.Three-dimensional electro anatomic mapping has proven as accurate as MRI and can
      be performed easily during AF ablation, thus providing a good tool for evaluation of atrial
      substrate during LPAF ablation.

      Although electro-anatomic mapping provided a desirable surrogate for delayed enhancement MRI
      to define AF substrate, there was an important technical issue to be considered. There were
      no good techniques to predict a desirable tip-tissue contact before the contact force
      catheter was applied. A poor tip-tissue contact could render the results of voltage mapping
      less reliable. On the other hand, excessively high contact force could increase the risk of
      steam pop and cardiac perforation during ablation. Hence it was important to use the contact
      force catheter to perform substrate mapping and ablation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atrial fibrillation free rate on or off antiarrhythmic drugs (AADs) after initial ablation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse event</measure>
    <time_frame>1 year</time_frame>
    <description>pericardial tamponade and thromboembolism event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of recurrent atrial flutter</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of pulmonary vein isolation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of acute pulmonary vein re-connection</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy exposure time</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ablation time</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Individualized substrate modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stepwise ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>individualized substrate modification</intervention_name>
    <description>CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.</description>
    <arm_group_label>Individualized substrate modification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stepwise ablation</intervention_name>
    <description>CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.</description>
    <arm_group_label>Stepwise ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 72years

          -  History of LPAF for ≥1 and ≤ 5 years

          -  Written informed consent provided

          -  Acceptance of catheter ablation treatment

          -  Acceptance of post-ablation follow-up

        Exclusion Criteria:

          -  Prior history of catheter ablation or surgical ablation

          -  Abnormal coagulation; contraindication for anti-coagulation

          -  left atrium diameter ≥ 55mm

          -  left atrium thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinhua Wang, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinhua Wang, MD,PHD</last_name>
    <phone>862168385206</phone>
    <email>ttwwxh@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Jiaotong University school of medicine,Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinhua Wang, MD,PHD</last_name>
      <phone>862168385206</phone>
      <email>ttwwxh@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012 Apr;9(4):632-696.e21. doi: 10.1016/j.hrthm.2011.12.016. Epub 2012 Mar 1.</citation>
    <PMID>22386883</PMID>
  </results_reference>
  <results_reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </results_reference>
  <results_reference>
    <citation>Chao TF, Tsao HM, Lin YJ, Tsai CF, Lin WS, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Hartono B, Chang HY, Ambrose K, Wu TJ, Chen SA. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):514-20. doi: 10.1161/CIRCEP.111.968032. Epub 2012 May 1.</citation>
    <PMID>22550126</PMID>
  </results_reference>
  <results_reference>
    <citation>Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, Hsu LF, Sanders P. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm. 2010 Jun;7(6):835-46. doi: 10.1016/j.hrthm.2010.01.017. Epub 2010 Jan 22. Review.</citation>
    <PMID>20206320</PMID>
  </results_reference>
  <results_reference>
    <citation>Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Jun;3(3):243-8. doi: 10.1161/CIRCEP.109.924878. Epub 2010 Mar 25.</citation>
    <PMID>20339034</PMID>
  </results_reference>
  <results_reference>
    <citation>Sawhney N, Anand K, Robertson CE, Wurdeman T, Anousheh R, Feld GK. Recovery of mitral isthmus conduction leads to the development of macro-reentrant tachycardia after left atrial linear ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):832-7. doi: 10.1161/CIRCEP.111.964817. Epub 2011 Sep 30.</citation>
    <PMID>21965530</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen M, Yang B, Chen H, Ju W, Zhang F, Tse HF, Cao K. Randomized comparison between pulmonary vein antral isolation versus complex fractionated electrogram ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2011 Sep;22(9):973-81. doi: 10.1111/j.1540-8167.2011.02051.x. Epub 2011 May 3.</citation>
    <PMID>21539635</PMID>
  </results_reference>
  <results_reference>
    <citation>Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, Schweikert RA, Saliba W, Cummings J, Burkhardt JD, Bhargava M, Belden WA, Abdul-Karim A, Natale A. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005 Jan 18;45(2):285-92.</citation>
    <PMID>15653029</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, McGann CJ, Akoum N, Kholmovski E, Macleod RS, Marrouche NF. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm. 2010 Oct;7(10):1475-81. doi: 10.1016/j.hrthm.2010.06.030. Epub 2010 Jul 1.</citation>
    <PMID>20601148</PMID>
  </results_reference>
  <results_reference>
    <citation>Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, Sparks PB, Morton JB, Kalman JM. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol. 2012 Mar;23(3):232-8. doi: 10.1111/j.1540-8167.2011.02178.x. Epub 2011 Sep 28.</citation>
    <PMID>21955090</PMID>
  </results_reference>
  <results_reference>
    <citation>Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009 Apr 7;119(13):1758-67. doi: 10.1161/CIRCULATIONAHA.108.811877. Epub 2009 Mar 23.</citation>
    <PMID>19307477</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JH, Pak HN, Choi EJ, Jang JK, Kim SK, Choi DH, Choi JI, Hwang C, Kim YH. The relationship between endocardial voltage and regional volume in electroanatomical remodeled left atria in patients with atrial fibrillation: comparison of three-dimensional computed tomographic images and voltage mapping. J Cardiovasc Electrophysiol. 2009 Dec;20(12):1349-56. doi: 10.1111/j.1540-8167.2009.01557.x.</citation>
    <PMID>19602027</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>long standing persistent atrial fibrillation</keyword>
  <keyword>novel approach</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

